CAL-101,a novel agent of targeted therapy in hematological malignancies / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 530-533, 2014.
Article
en Zh
| WPRIM
| ID: wpr-349676
Biblioteca responsable:
WPRO
ABSTRACT
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. It has been determined that the P110δ isoforms of PI3K expressed primarily in cells of hematopoietic lineage, such as B and T cells. This review focuses on the target, mechanism of action, the use and prospect of CAL-101 in tumors of blood and lymph systems.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Farmacología
/
Purinas
/
Transducción de Señal
/
Neoplasias Hematológicas
/
Usos Terapéuticos
/
Quimioterapia
/
Quinazolinonas
/
Fosfatidilinositol 3-Quinasa Clase Ia
Límite:
Animals
/
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Año:
2014
Tipo del documento:
Article